Screener
Sionna Therapeutics SION Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $18,963 | $13,668 |
| General and administrative | 10,636 | 5,991 |
| Total operating expenses | 29,599 | 19,659 |
| Loss from operations | (29,599) | (19,659) |
| Other income: | ||
| Interest income | 2,820 | 3,000 |
| Other income | — | 177 |
| Total other income | 2,820 | 3,177 |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's operating income?
- Sionna Therapeutics (SION) reported operating income of -$29.6M in Q1 2026.
- How has Sionna Therapeutics's operating income changed year-over-year?
- Sionna Therapeutics's operating income decreased by 50.6% year-over-year, from -$19.66M to -$29.6M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Sionna Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude